prolinedithiocarbamate has been researched along with Lupus Erythematosus, Systemic in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, H; Chen, J; Geng, L; Hou, Y; Li, X; Lu, L; Shi, S; Sun, L; Tang, Y; Xie, H; Zeng, X | 1 |
1 trial(s) available for prolinedithiocarbamate and Lupus Erythematosus, Systemic
Article | Year |
---|---|
Activated NF-κB in bone marrow mesenchymal stem cells from systemic lupus erythematosus patients inhibits osteogenic differentiation through downregulating Smad signaling.
Topics: Adult; Antineoplastic Agents; Bone Marrow Cells; Bone Morphogenetic Protein 2; Cell Differentiation; Cells, Cultured; Down-Regulation; Female; Humans; Lupus Erythematosus, Systemic; Male; Mesenchymal Stem Cells; Middle Aged; NF-kappa B; Osteoblasts; Osteogenesis; Phosphorylation; Proline; Signal Transduction; Smad Proteins; Thiocarbamates; Tumor Necrosis Factor-alpha | 2013 |